Fig. 1.
Fig. 1. Treatment scheme of the ANLL91 regimen for infant AML. / The use of each drug was as follows. Induction: etoposide, 2 hours drip IV (intravenous) for 5 days; cytarabine (AraC), 2 hours drip IV for 7 days; mitoxantrone, IV for 5 days. Courses 1 and 2: HD-AraC, 3 hours drip IV twice a day for 3 days; etoposide, 2 hours drip IV for 5 days; mitoxantrone, IV. Courses 3 and 4: AraC, 20 hours drip IV for 5 days; etoposide, 2 hours drip IV for 5 days; THP-ADR, 2 hours drip IV. Courses 5 and 6: HD-AraC, 3 hours drip IV for 5 days; etoposide, 2 hours drip IV for 5 days; aclarubicin, IV for 3 days. Courses 7 and 8: HD-AraC, 3 hours drip IV for 5 days; etoposide, 2 hours drip IV for 5 days; VCR, IV. As a CNS prophylaxis, intrathecal methotrexate, Ara-C, and hydrocortisone were used in induction and each course of intensification therapy.

Treatment scheme of the ANLL91 regimen for infant AML.

The use of each drug was as follows. Induction: etoposide, 2 hours drip IV (intravenous) for 5 days; cytarabine (AraC), 2 hours drip IV for 7 days; mitoxantrone, IV for 5 days. Courses 1 and 2: HD-AraC, 3 hours drip IV twice a day for 3 days; etoposide, 2 hours drip IV for 5 days; mitoxantrone, IV. Courses 3 and 4: AraC, 20 hours drip IV for 5 days; etoposide, 2 hours drip IV for 5 days; THP-ADR, 2 hours drip IV. Courses 5 and 6: HD-AraC, 3 hours drip IV for 5 days; etoposide, 2 hours drip IV for 5 days; aclarubicin, IV for 3 days. Courses 7 and 8: HD-AraC, 3 hours drip IV for 5 days; etoposide, 2 hours drip IV for 5 days; VCR, IV. As a CNS prophylaxis, intrathecal methotrexate, Ara-C, and hydrocortisone were used in induction and each course of intensification therapy.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal